Peer-reviewed articles
PBC–AIH variant syndrome: emerging new terminology and a new approach to diagnosis and management
The causal relationship between inflammatory bowel disease and primary biliary cholangitis
Efficacy and safety of Seladelpar in the treatment of primary biliary cholangitis: a systematic review and meta-analysis
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
Effectiveness and tolerability of bezafibrate in primary biliary cholangitis – a nationwide real-world study
Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendations
High biochemical remission rates in patients with primary biliary cholangitis treated with “triple” anticholestatic therapy
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers
Integrating Machine Learning and Multiomics Analyses to Identify Immune-Related Biomarkers and Mechanisms in Primary Biliary Cholangitis
Primary Biliary Cholangitis in 2025: A New Frontier
The impact of deep response to ursodeoxycholic acid in primary biliary cholangitis – should it be the new clinical standard?
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Primary biliary cholangitis: Personalizing second-line therapies
PBC-HOPE: A randomized controlled trial of hypnosis and psychoeducation in women with primary biliary cholangitis and fatigue
© 2026 Wolters Kluwer. All right reserved.